Limit on the Fierz Interference Term b from a Measurement of the Beta Asymmetry in Neutron Decay.

In the standard model of particle physics, the weak interaction is described by vector and axial-vector couplings only. Nonzero scalar or tensor interactions would imply an additional contribution to the differential decay rate of the neutron, the Fierz interference term. We derive a limit on this hypothetical term from a measurement using spin-polarized neutrons.

Measurement of the Weak Axial-Vector Coupling Constant in the Decay of Free Neutrons Using a Pulsed Cold Neutron Beam.

We present a precision measurement of the axial-vector coupling constant g_{A} in the decay of polarized free neutrons. For the first time, a pulsed cold neutron beam was used for this purpose. By this method, leading sources of systematic uncertainty are suppressed.

Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site.

A series of non-covalent inhibitors of the serine protease dipeptidyl peptidase IV (DPP-IV) were found to adopt a U-shaped binding conformation in X-ray co-crystallization studies. Remarkably, Tyr547 undergoes a 70 degrees side-chain rotation to accommodate the inhibitor and allows access to a previously unexposed area of the protein backbone for hydrogen bonding.

Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.

Incretin levels approach normal physiological values following treatment with dipeptidyl peptidase (DPP)-IV inhibitors. This is in contrast to incretin levels resulting from the exogenous administration of glucagon-like peptide (GLP)-1 and its analogs, which can reach super-physiological values. This review describes the role of DPP-IV inhibitors as incretin enhancers in the regulation of glucose homeostasis in type 2 diabetic patients.

Structure activity studies of the serine-AIB dipeptide domain in 2,3-dihydroisothiazole based growth hormone secretagogues.

A series of growth hormone secretagogues (GHSs) based on 2,3-dihydroisothiazole has been synthesized in the search for a potential treatment of growth hormone deficiency or frailty in the elderly. This paper describes the evaluation of the SAR of the benzyl-D-Ser-aminoisobutyric acid dipeptide fragment. Introduction of substituents in the peptide backbone and in the phenyl ring has been investigated, as well as replacements for the benzyl group and for the AIB residue.